My Mahoney's Biography

My Mahoney, Professor and Vice Chair, Thomas Jefferson University

Currently a Professor and Vice Chair of Equal Opportunity and Workforce Diversity, Department of Dermatology & Cutaneous Biology at Thomas Jefferson University.

Joint appointment in Biochemistry & Molecular Biology and a member of the Sidney Kimmel Cancer Center. Permanent reviewer for the Arthritis and Musculoskeletal and Skin Diseases (AMS) Special Grants Review Committee for the NIH. At TJU, a founding member of the Reprogramming to Revive Regeneration and Stimulate Tissue and Organ Repair (R?STORE) group whose goal is to assess the cellular networks that stimulate tissue and organ regeneration for functional repair. Also belong to the Squamous Cell Carcinoma Tumor Ecology and Microenvironment (STEM) Research Group whose goal is to address how interactions in the tumor microenvironment (TME) be used to prevent disease progression and treatment resistance in SCC.

Modulation of Extracellular Vesicle Release and Content in SCC Cells

Wednesday, 27 March 2019 at 15:00

Add to Calendar ▼2019-03-27 15:00:002019-03-27 16:00:00Europe/LondonModulation of Extracellular Vesicle Release and Content in SCC CellsCirculating Biomarkers World Congress 2019 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com

Emerging as critical in the pathobiology of cancer are nanosized extracellular membrane vesicles (EVs) secreted by tumor cells into the blood and other bodily fluids carrying molecular constituents to modulate local and distant tumor microenvironment. EVs can be taken up by recipient cells and can modulate diverse biological processes including cell polarity and tissue morphogenesis and represent novel and valuable circulating biomarkers for tumor prognosis and diagnosis. Thus, defining factors that affect the release or modify the content of EVs is critical to our understanding of not only normal tissue development but also malignant transformation and progression. We have shown that the cadherin desmoglein 2 (Dsg2), an important regulator of growth and survival signaling pathways, drives tumorigenesis in experimental models, and clinical samples confirm that Dsg2 is indeed overexpressed in those cancers. We observed that Dsg2 is enriched in EVs derived from SCC cells and patient sera. Dsg2 modulates EV release and mitogenic content including EGFR and c-Src. Dsg2-labeled EVs are taken up by dermal fibroblasts, activating Erk1/2 and Akt signaling and promoting cell proliferation. Our work thus far defines a mechanism by which cancer cells can modulate the tumor microenvironment, a step critical for tumor progression.

Add to Calendar ▼2019-03-27 00:00:002019-03-29 00:00:00Europe/LondonCirculating Biomarkers World Congress 2019Circulating Biomarkers World Congress 2019 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com

Corporate Sponsors